BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1550082)

  • 1. Analysis of treatment failure in acute nonlymphocytic leukemia patients over fifty years of age. A Southwest Oncology Group study.
    Ryan DH; Kopecky KJ; Head D; Grever MR; Shiaer SM; Lipschitz DA; Hynes HE; Vial RH; Veith RW; Gumbart CH
    Am J Clin Oncol; 1992 Feb; 15(1):69-75. PubMed ID: 1550082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: a Southwest Oncology Group study.
    Bigelow CL; Kopecky K; Files JC; Head D; Lipschitz DA; Grever M; Appelbaum FR
    Am J Hematol; 1995 Apr; 48(4):228-32. PubMed ID: 7717369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA.
    Mandelli F; Vegna ML; Avvisati G; Amadori S; Spadea A; Cacciola E; Cantore N; De Laurenzi A; De Rosa C; Fioritoni G
    Ann Hematol; 1992 Apr; 64(4):166-72. PubMed ID: 1581404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of induction chemotherapy dose and dose intensity on the duration of remission in acute myeloid leukemia. Australian Leukemia Study Group.
    Bishop JF; Matthews JP; Young G; Szer J; Joshua DE; Dodds A; Laidlaw CR; Cobcroft R; Herrman R; Ma D
    Leuk Lymphoma; 1994 Sep; 15(1-2):79-84. PubMed ID: 7858505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
    Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
    Bishop JF; Lowenthal RM; Joshua D; Matthews JP; Todd D; Cobcroft R; Whiteside MG; Kronenberg H; Ma D; Dodds A
    Blood; 1990 Jan; 75(1):27-32. PubMed ID: 2403818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose cytosine arabinoside as consolidation chemotherapy for acute nonlymphocytic leukemia in remission.
    Urabe A; Mizoguchi H; Hoshino S; Nomura T; Dan K; Toyama K; Kimura M; Ogawa T; Yamaguchi H; Mutoh Y
    Int J Hematol; 1991 Feb; 54(1):75-7. PubMed ID: 1954354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine.
    Kalwinsky DK; Dahl GV; Mirro J; Jackson CW; Look AT
    Med Pediatr Oncol; 1986; 14(5):245-50. PubMed ID: 2431255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group.
    Lazarus HM; Vogler WR; Burns CP; Winton EF
    Cancer; 1989 Mar; 63(6):1055-9. PubMed ID: 2917307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The curative treatment of adult acute nonlymphocytic leukemia].
    Uzuka Y; Saito Y
    Rinsho Ketsueki; 1989 Aug; 30(8):1163-6. PubMed ID: 2601025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Ochs J; Rivera GK; Pollock BH; Buchanan G; Crist W; Freeman AI
    Cancer; 1990 Oct; 66(8):1671-7. PubMed ID: 2208021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia.
    Osman I; Akin U; Ismet A; Meral B; Hamdi A; Haluk K
    Haematologia (Budap); 1996; 27(2):93-7. PubMed ID: 14651226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
    Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia.
    Woods WG; Ruymann FB; Lampkin BC; Buckley JD; Bernstein ID; Srivastava AK; Smithson WA; Benjamin DR; Feig SA; Kim TH
    Cancer; 1990 Sep; 66(6):1106-13. PubMed ID: 2205352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study.
    Steuber CP; Civin C; Krischer J; Culbert S; Ragab A; Ruymann FB; Ravindranath Y; Leventhal B; Wilkinson R; Vietti TJ
    J Clin Oncol; 1991 Feb; 9(2):247-58. PubMed ID: 1988573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.